6/19/07 - Monarch LifeSciences Enters Agreement with GeneGo
MONARCH LIFESCIENCES ENTERS AGREEMENT WITH GENEGO TO OFFER PATHWAY ANALYSIS SERVICES USING 1-2-3 WORKFLOW
St. Joseph, MI. June 25th 2007 –GeneGo, Inc., the leading systems biology tools company, announced today that Monarch LifeSciences will be offering pathway analysis add on services to their customers. Monarch is a contract research organization with expertise in protein biomarker biomarker discovery, development and validation. The “1-2-3 Workflow” from GeneGo automatically uploads proteomics data, compares the datasets, identifies common, similar and unique components of the datasets, conducts enrichment analysis in multiple ontologies such as diseases, canonical pathways and functional processes; calculated the most relevant networks and the focal hub proteins. The end product is a comprehensive Word report.
“We are very pleased to be working with Monarch as they offer excellent proteomics services, which is a growing OMICs field,” said Julie Bryant, GeneGo’s VP of Business Development. “Our goal in development of 1-2-3 Workflow was to adapt our functional data analysis technology for occasional users, which means automation and ease of use without a compromise on quality. We believe that Monarch LifeSciences’ customers will be very happy with the analysis provided”
”Our goal is to provide our customers with reliable proteomics data than can easily integrate into their research programs,” said Lauri Caviston, Monarch LifeSciences’ VP of Business Development. “GeneGo provides an excellent tool for taking the data we generate to the next level”
About GeneGo
GeneGo develops systems biology technology for life science research. The original computational MetaDiscoveryTM platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 4.3TM, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug2.0TM is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBaseTM represents the knowledge base for MetaCore. For more information, please visit the company's web site at
www.genego.com
MetaCore™, MetaBaseTM, MetaDrugTM , MetaLinkTM, MetaDiscoveryTM, MetaToxTM and MetaMinerTM , 1-2-3 WorkflowTM are trademarks of GeneGo, Inc.
About Monarch LifeSciences:
Monarch LifeSciences provides services in protein biomarker discovery, development and validation for the pharmaceutical and biotech industries. Monarch’s biomarker discovery services include experimental design, proprietary sample preparation methods and quantification algorithms to ensure the generation of quality data. The LifeMarker™ Assay supports both pre-clinical and clinical applications of biomarkers and provides accurate high throughput analysis of proteins without the need for an antibody. For more information, please visit the company’s web site
www.monarchlifesciences.com